Using FTT PET/CT scans to evaluate PARP activity in metastatic prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study involves up to 30 men with metastatic prostate cancer who will undergo two FTT PET/CT scans to assess PARP activity in known cancer sites. Participants will have a baseline scan before starting a new therapy and an optional follow-up scan shortly after treatment begins. The study aims to compare imaging results with tissue samples to evaluate the effectiveness of the investigational radiotracer FTT in identifying PARP-1 expression. Treatment decisions will be made based on clinical criteria rather than the imaging results.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants will be ≥ 18 years of age
2. Histologically proven prostate carcinoma
3. Clinical evidence of metastatic disease with at least one lesion identified on standard of care imaging (CT, MRI, Bone Scan, FDG or other PET/CT, Ultrasound)
4. Considered a candidate for new therapy or change in therapy with PARP inhibitor therapy and/or androgen deprivation therapy (ADT) and/or chemotherapy with or without additional agents, either on a clinical trial or as part of clinical care.
5. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria:

1. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
2. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study

Where it's running

• University of Pennsylvania Hospital
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Neil Taunk, MD — University of Pennsylvania
• Study coordinator: Erin Schubert, BA
• Email: erin.schubert@pennmedicine.upenn.edu
• Phone: 215-573-6569

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Epidemiology, diagnosis, and treatment patterns of prostate cancer in Algeria

  This project collects medical and treatment information to see how prostate cancer is diagnosed and managed in Algerian men with confirmed disease.

  Recruiting at 21 sites Société Algérienne de Formation et Recherche en Oncologie · Adrar, Algeria and 23 other locations · NCT07484971

• OM-RCA-01 (anti-FGFR1 antibody) for metastatic tumors that express FGFR1

  This trial will try OM-RCA-01, an IV antibody given every two weeks, in adults with metastatic cancers whose tumors test positive for FGFR1 and who have progressed after standard treatments.

  Recruiting at 4 sites Phase 1/2 Kidney Cancer Research Bureau · Kazan' and 4 other locations · NCT07292168

• First-in-human testing of repeated autologous TIL immunotherapy for metastatic colorectal and prostate cancer

  This trial tests whether repeated infusions of a patient’s own tumor-infiltrating lymphocytes (TILs) can persist longer in the blood and help people with metastatic colorectal or prostate cancer.

  Recruiting Phase 1/2 CuraCell TX AB · Frankfurt · NCT07255664

• PSMA PET to predict treatment response in advanced prostate cancer

  This will test whether PSMA PET scans can help predict how advanced prostate cancer will respond to systemic treatments such as hormone therapy, chemotherapy, or PSMA-targeted radioligand therapy.

  Recruiting at 4 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Italy and 3 other locations · NCT07089550

• Treatment for advanced prostate cancer using Pluvicto

  This study is testing if a new treatment called Pluvicto can help men with advanced prostate cancer that has spread to their bones feel better and improve their quality of life.

  Recruiting Phase 2 Excel Diagnostics and Nuclear Oncology Center · Houston, Texas · NCT06972628

• 7-day water-only fasting for metastatic prostate cancer

  This study will test whether a 7-day water-only fast (with a ketogenic very low-calorie option) is safe and doable for people with metastatic prostate cancer.

  Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06826924

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.